• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Bio-Medical Sciences (Bio-Medical)
    • School of Bio-Medical Sciences (Bio-Medical) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Bio-Medical Sciences (Bio-Medical)
    • School of Bio-Medical Sciences (Bio-Medical) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Pharmacokinetics of cyclophosphamide in Burkitt's lymphoma patients attending Uganda Cancer Institute

    Thumbnail
    View/Open
    Masters Thesis (2.338Mb)
    Date
    2014-10
    Author
    Ojara, Williams Francis
    Metadata
    Show full item record
    Abstract
    Cyclophosphamide is one of the most widely used anticancer drugs. It forms part of various combinations used in treating a range of solid and hematologic tumours in both children and adults in Uganda. It is part of the regimen for treating Burkitt’s lymphoma, the most common of all cancers in Ugandan children. The drug has a narrow therapeutic index and large pharmacokinetic variability. A large proportion of administered regimens are associated with toxic outcomes. Treatment outcomes of cyclophosphamide correlate with its pharmacokinetics. Children show a greater variability in cyclophosphamide pharmacokinetics and as such are more prone to unpredictable treatment outcomes. The study investigated pharmacokinetics of the drug in Burkitt’s lymphoma patients; this would help optimise treatment in this group of patients. Methods The study targeted newly diagnosed Burkitt’s lymphoma patients (2-17 years) with normal renal and liver functions. A sparse sampling approach was adopted in which a maximum of 4 blood samples (4 mls per sample) were obtained within a 24 hr period from each patient. Plasma concentration of cyclophosphamide was determined by HPLC and the data analysed using NONMEM (NONMEM, version 7.2) with the First Order Conditional Estimation with Interaction. Results The study enrolled children; Median (Inter Quartile Range) characteristics; Age= 6(5-10) years, Weight=21(16-25) Kg, Body Surface Area= 0.8(0.7-0.96) m2, Serum Creatinine concentration = 30(26-34.7) µM, Alanine Amino Transferase = 15(11-30) U/L. The one compartmental model best fit the data. The estimates, (Mean ± S.D) of Clearence, Volume of distribution and Half Life were 1.12 ± 0.5 Litres/Hour, 18.9 ± 0.645 Litres and 11.69 Hours respectively. Patient weight was the only covariate investigated that significantly affected the pharmacokinetics of the drug. Conclusion Plasma clearence compares to literature reported values however volume of distribution is higher than what is reported; this may be associated with a longer than expected drug exposure.
    URI
    http://hdl.handle.net/10570/6293
    Collections
    • School of Bio-Medical Sciences (Bio-Medical) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV